ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

deucravacitinib

Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.

Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.

Drug pageDeucravacitinib: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 27, 202260 company-led studies, 12 open or runningNext primary completion: Nov 18, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb5912 open or runningphase 4since Jul 27, 2022Oct 3, 2016Nov 18, 2026phase 3 · NCT05946941
AbbVieits history only10 open or runningphase 4since Mar 21, 2024Mar 21, 2024none ahead

Also a collaborator on its studies: Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 44 earlier studies, Oct 3, 2016 to Jun 30, 2021.

  1. Jun 9, 2020Named deucravacitinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986165
  2. Jul 27, 2022Phase 4 study in PsoriasisNCT05478499 · 154 enrolled · United States, France, Germany and more
  3. Sep 23, 2022Phase 2 study in Alopecia AreataNCT05556265 · 94 enrolled · United States, Australia, Canada and more
  4. Nov 8, 20222 phase 3 studies in Lupus Erythematosus, SystemicNCT05617677, NCT05620407
  5. Jan 16, 2023Phase 4 study in PsoriasisNCT05701995 · 180 enrolled · United States, Puerto Rico
  6. Jul 7, 2023Phase 3 study in Sjogren's SyndromeNCT05946941 · 774 enrolled · United States, Argentina, Australia and more
  7. Sep 12, 2023Phase 4 study in Palmoplantar PsoriasisNCT06042920 · 130 enrolled · United States, Argentina, Canada
  8. Jun 21, 2024Phase 4 study in Healthy VolunteersNCT06476834 · 8 enrolled · United States
  9. Aug 21, 2024Phase 1 study in Healthy ParticipantsNCT06566768 · 52 enrolled · United Kingdom
  10. Jan 22, 2025Phase 1 study in Healthy ParticipantsNCT06851871 · 26 enrolled · United States
  11. Mar 6, 2025Phase 3 study in Arthritis, JuvenileNCT06869551 · 60 planned · United States, Brazil, Bulgaria and more
  12. Mar 12, 2025Phase 4 study in Lupus Erythematosus, SystemicNCT06875960 · 35 planned · United States
  13. May 13, 2025Phase 3 study in PsoriasisNCT06979453 · 366 planned · United States, Argentina, Belgium and more
  14. Aug 4, 2025Phase 3 study in Plaque PsoriasisNCT07116967 · 3,040 planned · United States, Argentina, Australia and more
  15. Aug 25, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07791199 · 2,300 planned

Ahead

  1. Nov 18, 2026Primary completion: phase 3 study in Sjogren's SyndromeNCT05946941
  2. Jan 31, 2028Primary completion: phase 4 study in Lupus Erythematosus, SystemicNCT06875960
  3. Jan 1, 2029Primary completion: phase 3 study in PsoriasisNCT04772079
  4. Oct 12, 2029Primary completion: phase 3 study in PsoriasisNCT06979453

TargetBeta

TYK2 →read by rule
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
HS-10374Hansoh Pharmaceutical Groupphase 36
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

All 59 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07791199Lupus Erythematosus, Systemic3Not yet recruitingOct 31, 20302,300
NCT07116967Plaque Psoriasis · United States, Argentina, Australia and more3RecruitingJan 16, 20313,040
NCT06979453Psoriasis · United States, Argentina, Belgium and more3RecruitingOct 12, 2029366
NCT06875960Lupus Erythematosus, Systemic · United States4RecruitingJan 31, 202835
NCT06869551Arthritis, Juvenile · United States, Brazil, Bulgaria and more3RecruitingMar 6, 203060
NCT06851871Healthy Participants · United States1CompletedApr 4, 202526
NCT06566768Healthy Participants · United Kingdom1CompletedJun 13, 202552
NCT06476834Healthy Volunteers · United States4CompletedNov 2, 20248
NCT06042920Palmoplantar Psoriasis · United States, Argentina, Canada4TerminatedApr 25, 2025130
NCT05946941Sjogren's Syndrome · United States, Argentina, Australia and more3Active, not recruitingNov 18, 2026774
NCT05701995Psoriasis · United States, Puerto Rico4CompletedAug 23, 2024180
NCT05620407Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3Active, not recruitingOct 19, 2026513
NCT05617677Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingOct 19, 2026516
NCT05556265Alopecia Areata · United States, Australia, Canada and more2TerminatedJan 6, 202494
NCT05478499Psoriasis · United States, France, Germany and more4CompletedJan 11, 2024154
NCT04949269Healthy Participants · United States1CompletedJan 3, 202261
NCT04908202Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingOct 10, 2024670
NCT04908189Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingNov 7, 2024729
NCT04877990Crohn Disease · United States, Australia, Canada and more2CompletedAug 29, 202367
NCT04857034Lupus Erythematosus, Discoid · United States, Argentina, Australia and more2Active, not recruitingAug 22, 202474
NCT04772079Psoriasis · Argentina, Australia, Brazil and more3RecruitingJan 1, 2029153
NCT04671953Healthy Participants · United States1CompletedMar 3, 202136
NCT04613518Colitis, Ulcerative · United States, Australia, Canada and more2CompletedMay 31, 202338
NCT04536961Healthy Volunteers · United Kingdom1CompletedDec 25, 202056
NCT04305899Healthy Participants · United States1CompletedNov 25, 202040
NCT04249284Healthy Participants · United States1CompletedMar 15, 202018
NCT04209699Healthy Participants · United States1CompletedFeb 4, 202018
NCT04167462Psoriasis · China, Korea, Republic of, Taiwan3CompletedMar 8, 2021220
NCT04113668Healthy Participants · United States1CompletedNov 19, 201948
NCT04086719Healthy Male Volunteers · United States1CompletedOct 29, 201916
NCT04065932Lupus · United Kingdom1CompletedDec 8, 201933
NCT04055506Healthy Participants · United States1CompletedSep 21, 201916
NCT04036435Psoriasis · United States, Australia, Canada and more3CompletedJul 21, 20261,466
NCT03979248Healthy · Netherlands1CompletedJul 7, 201921
NCT03956953Autoimmune Diseases · China1CompletedSep 25, 2019135
NCT03934216Colitis, Ulcerative · United States, Australia, Belgium and more2CompletedJun 13, 2021131
NCT03943147Lupus Nephritis · United States, Australia, Belgium and more2TerminatedOct 29, 202016
NCT03930602Healthy · United States1CompletedMay 27, 201916
NCT03924427Psoriasis · Japan3CompletedMar 24, 202174
NCT03920267Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2CompletedMar 21, 2025261
NCT03890809Liver Diseases · Czechia, Hungary, Slovakia1CompletedNov 30, 201932
NCT03890770Renal Insufficiency · United States, Czechia, Hungary and more1CompletedFeb 7, 202044
NCT03881059Active Psoriatic Arthritis · United States, Czechia, Germany and more2CompletedApr 27, 2020203
NCT03873415Psoriasis · United States1CompletedMay 1, 20199
NCT03739788Healthy Participants · United Kingdom1CompletedFeb 11, 20198
NCT03751228Healthy Participants · United States1CompletedNov 26, 20189
NCT03660436Healthy Participants · United States1CompletedOct 10, 2018131
NCT03624127Psoriasis · United States, Canada, China and more3CompletedSep 2, 2020666
NCT03611751Psoriasis · United States, Australia, Canada and more3CompletedNov 29, 20201,020
NCT03599622Crohn Disease · United States, Australia, Belgium and more2TerminatedDec 12, 2022239
NCT03541564Lupus Erythematosus, Systemic · United States1CompletedSep 4, 201884
NCT03419910Psoriasis · United States1CompletedMay 4, 201854
NCT03402087Arthritis, Psoriatic · Netherlands1CompletedMar 20, 201830
NCT03262727Lupus Erythematosus, Systemic · United States1CompletedNov 23, 201749
NCT03254784Lupus Erythematosus, Systemic · United States1CompletedNov 4, 201749
NCT03252587Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedJun 29, 2021363
NCT03044873Autoimmune Diseases · United States1CompletedMar 14, 201720
NCT03004768Psoriasis · United States1CompletedFeb 27, 20176
NCT02931838Psoriasis · United States, Australia, Canada and more2CompletedNov 16, 2017268

How it is read

Names in the registry

  • “BMS-986165”, 34 entries
  • “Deucravacitinib”, 21 entries
  • “BMS-986165 Tablet”, 2 entries
  • “BMS-986165 Dose A”, 1 entry
  • “BMS-986165 Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.